Husseini K. Manji, M.D. is Chief, Laboratory of Molecular Pathophysiology, Director for the Mood and Anxiety Disorders Program, NIMH, and Visiting Professor Department of Psychiatry, Columbia University College of Physicians & Surgeons. Dr. Manji received his B.S. (Biochemistry) and M.D. from the University of British Columbia. Following psychiatry residency training, he completed fellowship training in psychopharmacology at the NIMH and undertook extensive additional training in Cellular and Molecular Biology at the NIDDK. The major focus of his ongoing research is the investigation of disease- and treatment-induced changes in gene and protein expression profiles that regulate neuroplasticity and cellular resilience in mood disorders. In broad terms, his laboratories’ scientific goals are to capitalize upon recent insights into our understanding of the signaling pathways mediating the effects of mood stabilizers, in order to understand the pathophysiology of severe mood disorders and to develop improved therapeutics. He has received ongoing research funding from the NIH, Private Foundations, and pharmaceutical industry for his work on signaling pathways, gene expression and new medication development for severe mood disorders. Dr. Manji is a previous recipient of the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize (Nola Maddox Falcone Prize), the Mogens Schou Distinguished Research Award, the ACNP Joel Elkes Distinguished Research Award, the NIMH award for excellence in clinical care and research, the NIMH Outstanding Mentor award, the NIMH Supervisor of the Year Award, the Canadian Association of Professors in Psychiatry Award, and a Visiting Professor lectureship to the Salpetreire Hospital, Paris. He has published extensively on the molecular and cellular mechanisms of action of mood-stabilizing agents, and has edited a book on the mechanisms of action of antibipolar treatments. He is a councilor for the Collegium Internationale neuro-psychopharmacologicum (CINP), a member of the Canadian College of Neuropsychopharmacology , a fellow of the American College of Neuropsychopharmacology (ACNP), and chairs the ACNP’s Task Force on New Medication Development. He is currently sits on the NIMH Bipolar Initiative Scientific Advisory Board, is a member of the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) Scientific Advisory Committee, National Alliance for the Mentally Ill (NAMI) Center on Practice & Research Advisory Committee, the Child and Adolescent Bipolar Foundation Professional Advisory Council, the Scientific Advisory Board of the Juvenile Bipolar Research Foundation and the Stanley Medical Research Institute Scientific Advisory Board. Dr. Manji has also served as a member of the National Board of Medical Examiners Behavioral Science Test Committee, and the USMLE Step 1 Test Material Development Committee for Behavioral Science, and is the Director of the NIH Foundation for the Advanced Education in the Sciences Graduate Course in the Neurobiology of Mental Illness, co-chair, of the preclinical models workgroup of the NIMH Strategic Plan for mood disorders, and member of the NIH’s Roadmap initiative for multi-disciplinary research. Dr. Manji is currently editor of Neuroscience Perspectives, Biological Psychiatry, associate editor of the journal Bipolar Disorders, and sits on the Editorial Board of the official journal of the CINP.